Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHR-3996 in combination with tosedostat in relapsed/refractory multiple myeloma
2011-001914-33Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanatinostat and tosedostat in multiple myeloma (MM), sponsored by University of Leeds. Primary endpoint: Dose-limiting toxicities in cycle 1. Started Aug 2011; status: completed.
02
Drugs
nanatinostattosedostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2011-001914-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001914-33.